Abstract

A new class of nucleic acid substrates for AP endonucleases and members of the glycosylase/lyase family of enzymes is described. Representatives of each family, the enzymes Nfo and fpg, respectively, cleave nucleic acid backbones at positions in which a base has been replaced by a linker to which a variety of label moieties may be attached. The use of these synthetic substrates embedded within oligonucleotides is of utility in a number of applications.

IPC Classes  ?

• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention relates to methods and compositions for diagnosing SIRS, sepsis, severe sepsis, septic shock, or MODS in a subject, or assigning a prognostic risk for one or more clinical outcomes for a subject suffering from SIRS, sepsis, severe sepsis, septic shock, or MODS, the method comprising performing an immunoassay for CCL23 splice variant.

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

Methods and compositions for diagnosis, prognosis and monitoring of ovarian cancer and lung cancer are provided. Assays that detect NHERF-I (or one or more markers related thereto) and NHERF-I -containing complexes are used to assign a diagnosis to a subject being assessed for the presence of ovarian or lung cancer; assign a prognostic risk to a subject suffering from ovarian or lung cancer; or monitor the course of ovarian or lung cancer treatment in a subject.

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers

Abstract

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to monitor cardiorenal syndrome using assays that detect NGAL, preferably together with assays that detect natriuretic peptides such as BNP. Such methods and compositions can provide early indications of a deterioration in cardiorenal syndrome status, including prognosis regarding mortality and worsening renal function.

IPC Classes  ?

• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups

Abstract

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects in the context of renal artery stenosis (RAS). In particular, the invention relates to using assays that detect NGAL, their use to diagnose RAS in subjects suffering from hypertension, and their use in prognosis, particularly of mortality and worsening renal function.

IPC Classes  ?

• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups

Abstract

The present invention relates to methods and compositions for measuring latent protein C in test samples, particularly patient samples. The methods and compositions described are sensitive for latent protein C, relative to activated protein C.

IPC Classes  ?

• G01N 21/00 - Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
• G01N 21/64 - FluorescencePhosphorescence
• G01N 21/75 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
• G01N 21/76 - ChemiluminescenceBioluminescence
• G01N 25/18 - Investigating or analysing materials by the use of thermal means by investigating thermal conductivity
• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 39/44 - Antibodies bound to carriers